title: Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
abstract: This study provides information on the prevalence of the most important risk factors for osteoporosis and osteoporotic fracture in a large sample of women and men from the Valencia region and also provides the FRAX 10-year major and hip fracture risks for this population, as well as data about the use of diagnostic tests and antiosteoporotic treatments.
  
  
  BACKGROUND
  The purpose of this study was to describe demographic characteristics, osteoporosis risk factors, the 10-year risk of osteoporotic fracture, and the use of densitometry and antiosteoporotic treatments in the Valencia region, Spain.
  
  
  METHODS
  A cross-sectional study using the ESOSVAL cohort baseline data was conducted. We analyze the data from 5,310 women and 5,725 men aged 50 and over who attended to 272 collaborating primary care centers in 2009-2010. We collected the demographic, anthropometric, clinical, and pharmacy data from the electronic medical record.
  
  
  RESULTS
  The mean age of participants was 64.3 years old for women and 65.6 years old for men. The most frequent fracture risk factors were sedentary life (22.2 %) and previous fracture (15.8 %) in women and low calcium intake (21.4 %) and current smoker (20.9 %) in men. According to FRAX(®), the 10-year risk of presenting a major fracture was 5.5 % for the women and 2.8 % for the men. The 10-year risk for hip fracture was 1.9 and 1.1 % for the women and the men, respectively; 23.8 % of the women and 5.2 % of the men had a densitometry test, 27.7 % of the women and 3.5 % of the men were taking calcium and/or vitamin D supplements, and 28.2 % of the women (22.0 % in the 50-64 age group) and 2.3 % of the men were taking antiosteoporotic drugs.
  
  
  CONCLUSIONS
  The prevalence of certain fracture risk factors not included in the FRAX tool (sedentary life, falls, low calcium intake) is high. In young women, their low risks estimated by FRAX contrast with the high figures for densitometry testing and treatment.
authors.affiliation: Health Services Research Unit, Centro Superior de Investigación en Salud Pública, Avda de Cataluña 21, 46020 Valencia, Spain. sanfelix_jos@gva.es
authors.forename: J
authors.initials: J
authors.lastname: Sanfélix-Genovés
authors.forename: G
authors.initials: G
authors.lastname: Sanfélix-Gimeno
authors.forename: S
authors.initials: S
authors.lastname: Peiró
authors.forename: I
authors.initials: I
authors.lastname: Hurtado
authors.forename: C
authors.initials: C
authors.lastname: Fluixà
authors.forename: A
authors.initials: A
authors.lastname: Fuertes
authors.forename: J C
authors.initials: JC
authors.lastname: Campos
authors.forename: V
authors.initials: V
authors.lastname: Giner
authors.forename: C
authors.initials: C
authors.lastname: Baixauli
mesh_terms: D000058:Accidental Falls / Q000706:statistics & numerical data; D000368:Aged; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D058866:Osteoporotic Fractures / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D015995:Prevalence; D012008:Recurrence; D012307:Risk Factors; D057185:Sedentary Behavior; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D013030:Spain / Q000453:epidemiology
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary